MG
KLRS

Michael Gelband’s Kalaris Therapeutics KLRS Stock Holding History

Michael Gelband’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,005
Closed -$247K – 2145
2023
Q3 		$247K Buy
5,005
+3,880
+345% +$264K ﹤0.01% 1469
2023
Q2 		$88K Buy
+1,125
New +$107K ﹤0.01% 1759
2021
Q4 		– Sell
-690
Closed -$398K – 2686
2021
Q3 		$398K Buy
690
+81
+13% +$37.5K 0.01% 1505
2021
Q2 		$276K Buy
+609
New +$314K ﹤0.01% 1791

Other funds holding KLRS

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AIG
American International Group New York $2.93M AUM 12.08% 1-Year Est. Return

Michael Gelband's KLRS Position: Q4 2023 in Review

Michael Gelband sold out of Kalaris Therapeutics (KLRS) in Q4 2023, closing a stake of 5,005 shares — an estimated $247K sold.

Michael Gelband first reported a position in KLRS in Q2 2021 and held it in 4 quarters. The position peaked at $398K in Q3 2021. 81 funds tracked by Wall St. Rank hold KLRS as of Q4 2023.

  • Michael Gelband reported no remaining Kalaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Michael Gelband sold 5,005 Kalaris Therapeutics shares in Q4 2023, an estimated $247K.
  • Michael Gelband first reported a position in Kalaris Therapeutics in Q2 2021 and held it in 4 quarters.
  • Michael Gelband's Kalaris Therapeutics position peaked at $398K in Q3 2021.
  • 81 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2023.

Based on ExodusPoint Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.